- Home
- HIND vs MBAI Comparison
HIND vs MBAI Comparison
Compare HIND & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | HIND | MBAI |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | Israel |
| Employees | N/A | 85 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 12.0M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | HIND | MBAI |
|---|---|---|
| Price | $2.25 | $1.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 21.3K | ★ 86.5K |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $1.31 |
| 52 Week High | $12.87 | $3.92 |
Technical Indicators
Market Signals| Indicator | HIND | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 49.92 |
| Support Level | $2.02 | $1.38 |
| Resistance Level | $2.93 | $1.89 |
| Average True Range (ATR) | 0.15 | 0.19 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 64.63 | 30.99 |
Price Performance
Historical ComparisonAbout HIND Vyome Holdings Inc.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.
About MBAI Check-Cap Ltd. Ordinary Share
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.